Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

The aim of this study has been to investigate the potential of serum biomarkers used in clinical practice (CEA, CYFRA 21–1, SCC) together with the serum epidermal growth factor receptor (EGFR) and its associated ligands (EGF, TGF-α, HB-EGF) as outcome predictors of non-small cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero-Ventosa, Elena Yaiza, Blanco-Prieto, Sonia, González-Piñeiro, Ana Lourdes, Rodríguez-Berrocal, Francisco Javier, Piñeiro-Corrales, Guadalupe, Páez de la Cadena, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402684/
https://www.ncbi.nlm.nih.gov/pubmed/25918681
http://dx.doi.org/10.1186/s40064-015-0891-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402684/
https://www.ncbi.nlm.nih.gov/pubmed/25918681
http://dx.doi.org/10.1186/s40064-015-0891-0

Ejemplares similares